Posted by Michael Wonder on 23 Mar 2026
Ionis announces zilganersen new drug application for Alexander disease accepted by FDA for priority review
23 March 2026 - Ionis Pharmaceuticals today announced that the US FDA has accepted for priority review the new drug application for zilganersen, an investigational RNA targeted medicine for Alexander disease, a rare, progressive and often fatal neurological condition.
The FDA has set a PDUFA target action date of 22 September 2026.
